Autopsy report · NCT02225275

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

“Due to slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 7 months before it started.
• Ran for about 5 years 2 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma

Interventions

Lenalidomide; Obinutuzumab

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Staging Procedures to Diagnose Malignant Pleural Mesothelioma
  “due to low/slow accrual” (94% match in meaning)
• Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
  “Slow accrual” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.